Milestone follows nearly US$7 million in seed investment and strategic support from SOLVE FSHD VANCOUVER, British Columbia–(BUSINESS WIRE)–SOLVE FSHD, a venture-philanthropy organization dedicated to accelerating therapies for facioscapulohumeral muscular dystrophy (FSHD), today celebrated the closing of a US$37 million Series A financing by portfolio company Altay Therapeutics, Inc. The financing was co-led by Sound Bioventures …
VANCOUVER, Canada – SOLVE FSHD today announced new nonclinical data supporting SFH-4090 for the treatment of facioscapulohumeral muscular dystrophy (FSHD). The data were presented at the 31st Annual Congress of the World Muscle Society (WMS). SFH-4090, also known as MT-4090, discovered by Tanabe Pharma Corporation (Head Office: Osaka, Japan; Representative Director, CEO: Akihisa Harada), is …
ABINGTON, Mass. and VANCOUVER, BC, July 30, 2026 /PRNewswire/ — The FSHD Society, SOLVE FSHD, and the FSHD Clinical Trial Research Network (FSHD CTRN) today announced significant momentum for the FSHD Industry Collaborative, including the addition of four new biopharma sponsors and meaningful early progress across all active research workstreams. Launched in April 2026, the …
Oversubscribed financing co-led by Octagon Capital and Janus Henderson Investors, with participation from Fidelity Management & Research Company, Cormorant Asset Management, Duquesne Family Office, Sanofi Ventures, funds managed by abrdn Inc., Angelini Ventures, Readout Capital, and existing investorsProceeds will support pivotal clinical development of EPI-321, the first epigenetic therapy for facioscapulohumeral muscular dystrophy (FSHD) and …
Interim data demonstrated a favorable safety profile and early evidence of disease modification, including statistically significant increases in lean muscle volume and biomarker changes consistent with DUX4 suppression Additional clinical data expected to be presented at the World Muscle Society Annual Congress in September 2026 SAN FRANCISCO–(BUSINESS WIRE)–Epicrispr Biotechnologies, a clinical-stage company pioneering epigenetic therapies, …
Single-Dose EPI-321 Demonstrated a Positive Safety Profile and Increased Lean Muscle Volume Across the First Three Evaluable Patients at Six MonthsEPI-321 is the First Investigational Therapy Designed to Silence DUX4, the Genetic Driver of FSHD SAN FRANCISCO, CA – June 26, 2026 – Epicrispr Biotechnologies, a clinical-stage company pioneering epigenetic therapies, today announced new interim data …